Emeryville, United States
Dynavax Technologies, a Sanofi Company, is a commercial-stage biopharmaceutical firm that stands out in the global healthcare sector through its development and commercialization of innovative vaccines targeting infectious diseases. With strategic presence in the United States, Dynavax plays a pivotal role in vaccine advancements.
The company’s portfolio includes two key commercial products: the HEPLISAV-B® vaccine and the CpG 1018® adjuvant. The HEPLISAV-B® vaccine is significant for its approval in various major markets, such as the U.S., the European Union, and the United Kingdom, enhancing protection against hepatitis B in adults over 18. Moreover, the CpG 1018® adjuvant broadens its valuable applications within both the HEPLISAV-B® and numerous adjuvanted COVID-19 vaccines.
Although specific founding details and investment rounds are unavailable, Dynavax represents a resilient entity within pharmaceuticals, bolstered by its association with Sanofi. This alignment underscores robust support and potential for continued innovation in a competitive industry.
